Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit 7-01-2026, 01:34

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia 23-09-2024, 12:00

Gluco Extend Reviews (2025): Investigative Report on Its Blood Sugar & Insulin Support Benefits In 2025 22-03-2025, 02:05